Phreesia (PHR) Azione Prezzo
Phreesia Prezzo
Il fatturato è cresciuto a un tasso composto del 26,4% annuo negli ultimi 8 anni, raggiungendo 473,64 Mio. USD. Il margine netto di Phreesia si attesta al 0,5%, in aumento rispetto al -56,0% di alcuni anni fa. Gli analisti fissano un target di prezzo mediano di 12,00 USD, ovvero il 2,5% sotto il prezzo attuale. Su 22 analisti, 13 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Phreesia Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Phreesia Azione e analisi azionaria
Domande frequenti sull'azione Phreesia
The business model of Phreesia Inc is centered around providing patient intake and engagement solutions to healthcare organizations. By offering a comprehensive platform, Phreesia streamlines the registration process, collects patient information, verifies insurance eligibility, and facilitates payments. Their services aim to enhance operational efficiency, improve patient experience, and drive revenue growth for clients. Through innovative technology and data analytics, Phreesia empowers healthcare providers to effectively streamline their workflows, optimize patient care, and increase financial performance. The company focuses on delivering value to healthcare organizations by improving the patient journey and enabling a better patient-provider relationship.
Phreesia Inc is primarily active in the healthcare industry.
Some of the main competitors of Phreesia Inc in the market include athenahealth, Cerner Corporation, and athenathealth.
Phreesia Inc is a leading healthcare technology company that specializes in patient intake solutions. Founded in 2005, Phreesia has revolutionized the way healthcare organizations collect patient information, automate workflows, and enhance the patient experience. With their innovative platform, Phreesia has helped thousands of healthcare providers streamline their operations and improve patient engagement. By offering a patient-centric approach, Phreesia has become a trusted partner in the industry, empowering healthcare organizations to deliver high-quality care while reducing administrative burdens. With a strong track record of success and a commitment to innovation, Phreesia continues to be at the forefront of transforming healthcare delivery.
Phreesia Inc has achieved several significant milestones over the years. One of the notable achievements is their successful initial public offering (IPO) in July 2019, which allowed the company to raise substantial capital to fuel their growth. Furthermore, Phreesia has consistently expanded its client base, forging partnerships with numerous leading healthcare organizations across the United States. The company's innovative platform, which streamlines patient intake and payment processes, has garnered recognition and accolades, including being named one of the "50 Most Innovative Companies" by Fast Company in 2020. Phreesia's commitment to driving healthcare efficiency and enhancing patient experiences has positioned them as a prominent player in the industry.
Phreesia Inc is primarily present in the United States.
Phreesia Inc is a healthcare technology company that aims to improve patient experiences and streamline administrative tasks. With a focus on innovation and efficiency, Phreesia provides a comprehensive platform for healthcare providers to manage patient intake, payments, and engagement. The company's corporate philosophy revolves around empowering patients, enhancing clinical decision-making, and improving healthcare outcomes. By leveraging cutting-edge technology and patient-centric solutions, Phreesia strives to revolutionize the healthcare industry. Through its robust platform and commitment to delivering a seamless experience, Phreesia Inc showcases a dedication to advancing patient care and transforming the healthcare landscape.
Gli analisti fissano attualmente un prezzo obiettivo medio di 12,17 USD per l’azione Phreesia (mediana: 12,00 USD), pari a -1,1 % rispetto all’ultimo prezzo. Il consenso si basa su 22 giudizi di analisti.
22 analisti valutano attualmente l’azione Phreesia: 13 raccomandano l’acquisto, 9 la tenuta e 0 la vendita.
Convertita al tasso di cambio attuale, l’azione Phreesia quota 10,97 EUR (12,31 USD).
L’azione Phreesia (PHR) è quotata su 5 borse, tra cui: NYSE (PHR), London (0A23.L), Frankfurt (19P.F), München (19P.MU).
Phreesia Inc is a provider of technology-enabled services that optimize and improve patient traffic in medical practices and healthcare clinics. The company was founded in 2005 and is headquartered in New York City. Phreesia offers a wide range of services, such as patient registration, data entry, insurance verification, bill payment, appointment scheduling, and patient feedback. One of the company's most innovative products is the PhreesiaPad, an electronic tablet that automates paperwork during patient registration in the doctor's office. Phreesia has focused on the outpatient healthcare market, particularly medical practices and health centers, and has garnered numerous large clients, such as NewYork-Presbyterian Hospital and Duke University Medical Center. The company has developed comprehensive software that serves as the interface between physicians, insurance companies, and patients. Phreesia's core business is a subscription model, where customers pay a monthly fee to access the various services offered by the company. The company also partners with insurance companies to directly offer their services to patients. This leads to greater cost transparency and facilitates collaboration between physicians and insurance companies. Phreesia recently invested in telemedicine by partnering with SimplyWell, a digital health coaching company. This partnership allows Phreesia to offer a comprehensive platform for telemedicine and digital health solutions. Overall, Phreesia has developed a business model that enables easier collaboration and improves communication and transparency between physicians, patients, and insurance companies. By providing a comprehensive software solution that takes into account both the workflow in the practice and the requirements and expectations of patients, Phreesia has secured a solid position in the healthcare market.
Il fatturato di Phreesia ammonta a 473,64 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il profitto di Phreesia ammonta a 2,31 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Phreesia è attualmente 333,45. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Phreesia.
Il rapporto prezzo/fatturato (P/S) di Phreesia è attualmente 1,62. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Phreesia.
Il Quality Score AlleAktien per Phreesia è 4/10.
L'ISIN di Phreesia è US71944F1066. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Phreesia è A2PMY3. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Phreesia è PHR. Con questo simbolo di borsa vengono negoziate le azioni Phreesia in borsa.
Azione Phreesia
Gruppo di pari di Phreesia
Phreesia Ticker
Phreesia FIGI
Altre metriche e analisi di Phreesia in Deep Dive.
La nostra analisi azionaria dell'azione Phreesia include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Phreesia. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: